Imagion Biosystems is pleased to report that we closed the first quarter of FY2021 maintaining a strong cash balance and having added a new study site for our Phase I HER2 Breast Cancer Study. You can read more about the status and progress of the study and other key achievements in the quarter in our latest Appendix 4C and Quarterly Activity Report.
Executive Chairman Bob Proulx on Pitt Street Research’s Stocks Down Under Podcast: Getting ready for a Phase 2 Study
August 21, 2025
Earlier this month, our own Bob Proulx, Executive Chairman of Imagion Biosystems, had the opportunity to join Stuart Roberts on Pitt Street Research’s podcast Stocks